The FDA cleared Motivista, a prescription digital therapeutic, to treat negative symptoms of schizophrenia in adults in conjunction with clinician-managed outpatient care. The authorization was supported by results from the Phase 3 CONVOKE trial, in which patients using Motivista showed significantly greater improvement in negative symptoms than those using a control app, with strong user engagement and no serious treatment-related adverse events reported.